[go: up one dir, main page]

BR9709196A - Derivados de azetidinona para o tratamento de aterosclerose - Google Patents

Derivados de azetidinona para o tratamento de aterosclerose

Info

Publication number
BR9709196A
BR9709196A BR9709196A BR9709196A BR9709196A BR 9709196 A BR9709196 A BR 9709196A BR 9709196 A BR9709196 A BR 9709196A BR 9709196 A BR9709196 A BR 9709196A BR 9709196 A BR9709196 A BR 9709196A
Authority
BR
Brazil
Prior art keywords
atherosclerosis
treatment
azetidinone derivatives
azetidinone
derivatives
Prior art date
Application number
BR9709196A
Other languages
English (en)
Portuguese (pt)
Inventor
Colin Andrew Leach
Deirdre Mary Bernadette Hickey
Robert John Ife
Dashyant Dhanak
Colin Theobald
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9709196A publication Critical patent/BR9709196A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9709196A 1996-04-26 1997-04-15 Derivados de azetidinona para o tratamento de aterosclerose BR9709196A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds
PCT/EP1997/001898 WO1997041098A1 (en) 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
BR9709196A true BR9709196A (pt) 1999-05-25

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709196A BR9709196A (pt) 1996-04-26 1997-04-15 Derivados de azetidinona para o tratamento de aterosclerose

Country Status (17)

Country Link
EP (1) EP0915843A1 (es)
JP (1) JP2000509049A (es)
AR (1) AR006833A1 (es)
AU (1) AU2698697A (es)
BR (1) BR9709196A (es)
CA (1) CA2252696A1 (es)
CZ (1) CZ341098A3 (es)
HU (1) HUP9901359A3 (es)
ID (1) ID16660A (es)
IL (1) IL126696A0 (es)
MA (1) MA26426A1 (es)
NO (1) NO984939L (es)
NZ (1) NZ332476A (es)
PE (1) PE64398A1 (es)
PL (1) PL329530A1 (es)
TR (1) TR199802160T2 (es)
WO (1) WO1997041098A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437862T1 (de) 2000-02-16 2009-08-15 Smithkline Beecham Plc Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
CN1275949C (zh) 2001-03-28 2006-09-20 先灵公司 2-吖丁啶酮中间体化合物的对映体选择性合成
AR038956A1 (es) * 2001-05-25 2005-02-02 Schering Corp Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
WO2008140449A1 (en) 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
EP2155225B1 (en) 2007-05-11 2015-07-08 The Trustees of the University of Pennsylvania Methods of treatment of skin ulcers
UY33766A (es) 2010-12-06 2012-06-29 Glaxo Group Ltd COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
WO2012080497A2 (en) 2010-12-17 2012-06-21 Glaxo Group Limited Methods of treatment and prevention of eye diseases
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
TW201321382A (zh) 2011-07-27 2013-06-01 Glaxo Group Ltd 化合物
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
PE20151251A1 (es) 2013-01-25 2015-09-10 Glaxosmithkline Ip Dev Ltd Derivados [5,6] biciclicos de imidazo pirimidona con actividad sobre enzimas lp-pla2
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2014114249A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
EP4056571A4 (en) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL102582A0 (en) * 1991-07-23 1993-01-14 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0658205B1 (en) * 1993-06-25 2000-03-15 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
DE69434609T2 (de) * 1993-10-06 2006-09-21 Icos Corp., Bothell Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
MA23834A1 (fr) * 1994-12-22 1996-10-01 Smithkline Beecham Plc Procede de preparation de composes inhibiteurs de l'enzyme lp-pla2 et de compositions pharmaceutiques les contenant
WO1996029307A1 (en) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
TR199701762T1 (xx) * 1995-07-01 1998-05-21 Smithkline Beecham P.L.C. Damar t�kanmas� tedavisi i�in azetidinon t�revleri.
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
NO984939L (no) 1998-12-23
HUP9901359A2 (hu) 1999-08-30
MA26426A1 (fr) 2004-12-20
HUP9901359A3 (en) 2000-03-28
PE64398A1 (es) 1999-01-06
NZ332476A (en) 2000-06-23
CZ341098A3 (cs) 1999-03-17
JP2000509049A (ja) 2000-07-18
NO984939D0 (no) 1998-10-23
CA2252696A1 (en) 1997-11-06
AR006833A1 (es) 1999-09-29
WO1997041098A1 (en) 1997-11-06
EP0915843A1 (en) 1999-05-19
IL126696A0 (en) 1999-08-17
PL329530A1 (en) 1999-03-29
TR199802160T2 (xx) 1999-04-21
ID16660A (id) 1997-10-30
AU2698697A (en) 1997-11-19

Similar Documents

Publication Publication Date Title
BR9709196A (pt) Derivados de azetidinona para o tratamento de aterosclerose
FI972584A0 (fi) Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
ZA959100B (en) Azetidinone derivatives for the treatment of atherosclerosis
PT977748E (pt) Derivados benzopirano substituidos para o tratamento de inflamacao
BR9711530A (pt) Combina-Æo de terapia para tratamento de psicoses
FI954880L (fi) Käsiteltyjä epäorgaanisia kiintoaineita
PT946542E (pt) Derivados de indano ou de di-hidroindol
NO983266D0 (no) Distribuert Behandling
BR9505688A (pt) Atomizador de rotação
PT934320E (pt) Derivados de naftiridina
PT891332E (pt) Derivados de 6-fenilpiridil-2-amina
ID20531A (id) Alat pengobatan
DE69733470D1 (de) Laserbearbeitung
NO976158D0 (no) Azetidinon-derivater for behandling av atherosklerose
BR9709065A (pt) Derivados de alquilaminobenzotiazole e-benzoxazol
ID17723A (id) Senyawa untuk pengobatan
IS4789A (is) Meðferðarefnasambönd
NO983263L (no) Distribuert behandling
PT906279E (pt) Derivados de pirrol
PT931087E (pt) Novos derivados de piranosido
PT1051172E (pt) Metodo para tratamento da dpco
PT970080E (pt) Derivados de imino-aza-antraciclinona para o tartamento de amiloidoses
PT822287E (pt) Produto para tratamento de fibras
BR9706980A (pt) Derivados de isooxacefem
BR9708310A (pt) Derivados de 2-tioxotetrahidropirimidin-4-ona

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]